Skip to content
Home/Contractors/International Aids Vaccine Initiative INC.

Federal Contractor Profile

International Aids Vaccine Initiative INC.

Federal contracting record: $154M obligated across 31 awards from 2 agencies, FY 2016–2026.

$154M
Total Obligated
31
Award Records
2
Agencies Served
3
NAICS Codes

Company Profile

Parent UEI (Unique Entity Identifier)

ZEJBC8JQM3P5

CAGE Code

44YM6

Address

125 BROAD ST FL 9TH, NEW YORK, NY, 100042743

First Federal Award

Jul 14, 2016

Most Recent Award

Aug 21, 2026

Federal Sales Analytics

Toggle between trend, agency drilldown, and treemap. Use the period selector to focus the time window.

Hover any bar for YoY change + award count. Current fiscal year shown at reduced opacity (partial year).

Top Federal Agencies

Top NAICS Activity

  • 541714

    RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)

    12 awards

    $107M
  • 541715

    RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)

    3 awards

    $35M
  • 541712

    RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY)

    16 awards

    $12M

Recent Federal Awards

DateAgencyNAICSDescriptionAmount
Sep 11, 2026Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID541714HHSN272201800010I IAVI STORAGE OF GMP AND NON-GMP MATERIALS FOR NIAID BASE AWARD, CAN 8470038 FOR $435,313.50 CAN 8040917 FOR $435,313.50 TOTAL $870,627$375K
Sep 2, 2026Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID5417141800010I INTERNATIONAL AIDS VACCINE INITIATIVE TO V3 OBRA--2 BASE TASK ORDER FUNDING BIOD CAN 8470038 $642,953$679K
Jun 30, 2026Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID541715PRECLINICAL AND TRANSLATIONAL VACCINE DEVELOPMENT FOR HIV AND OTHER CANDIDATE AGENTS$385K
May 13, 2026Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID5417141800010I INTERNATIONAL AIDS VACCINE INITIATIVE MANUFACTURE OF HUMAN FLU CHALLENGE MATERIAL$89K
Apr 10, 2025Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID541715PRECLINICAL AND TRANSLATIONAL VACCINE DEVELOPMENT FOR HIV AND OTHER CANDIDATE AGENTS$3.4M
Aug 6, 2024Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA541714THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN$1.6M
Jul 31, 2024Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID541714CONTRACT HHSN272201800010I INTERNATIONAL AIDS VACCINE INITIATIVE MANUFACTURE OF INFLUENZA VIRUS HUMAN CHALLENGE MATERIAL FOR PHASE I AND II CLINICAL TESTING$70K
Jun 26, 2024Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID5417141800010I INTERNATIONAL AIDS VACCINE INITIATIVE MANUFACTURE OF HUMAN FLU CHALLENGE MATERIAL$137K
May 13, 2024Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID541715PRECLINICAL AND TRANSLATIONAL VACCINE DEVELOPMENT FOR HIV AND OTHER CANDIDATE AGENTS$209K
Apr 17, 2024Department of DefenseDEFENSE THREAT REDUCTION AGENCY541715ACCELERATED DEVELOPMENT OF A SARS-COV-2 VACCINE BASED ON THE LIVE VSVAG CHIMERIC VIRUS PLATFORM$960K
Dec 11, 2023Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID541714CONTRACT HHSN272201800010I INTERNATIONAL AIDS VACCINE INITIATIVE MANUFACTURE OF INFLUENZA VIRUS HUMAN CHALLENGE MATERIAL FOR PHASE I AND II CLINICAL TESTING$2.1M
Dec 7, 2023Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID541715PRECLINICAL AND TRANSLATIONAL VACCINE DEVELOPMENT FOR HIV AND OTHER CANDIDATE AGENTS$472K
Sep 26, 2023Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID541714CONTRACT HHSN272201800010I INTERNATIONAL AIDS VACCINE INITIATIVE MANUFACTURE OF INFLUENZA VIRUS HUMAN CHALLENGE MATERIAL FOR PHASE I AND II CLINICAL TESTING$1.5M
Sep 19, 2023Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID5417141800010I IAVI BASE AWARD $810,077 FY20 CELL LINE OPTIMIZATION AND PRE-MASTER BANK GENERATION FOR SB 301, A VACCINE FOR HEPATITIS B VIRUS (HBV) TOVM20V24VB 2 IID CAN 8470036$21K
Sep 13, 2023Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID541712THIS TASK ORDER IS TO DEVELOP AN OPTIMIZED PHASE 1 CGMP MANUFACTURING PROCESS FOR LIPID NANOPARTICLE (LNP) FABRICATION THAT ENABLE COVALENT COUPLING OF AN HIV-1 ENV TRIMER TO THE SURFACE OF THE LNP. A NON-GMP PROCESS RUN OF DRUG PRODUCT SHALL BE PERF$382K
Aug 16, 2023Department of DefenseDEFENSE THREAT REDUCTION AGENCY541715ACCELERATED DEVELOPMENT OF A SARS-COV-2 VACCINE BASED ON THE LIVE VSVAG CHIMERIC VIRUS PLATFORM$1.0M
Jul 21, 2023Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA541714THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN$18M
Jun 7, 2023Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID541712THIS TASK ORDER IS TO DEVELOP AN OPTIMIZED PHASE 1 CGMP MANUFACTURING PROCESS FOR LIPID NANOPARTICLE (LNP) FABRICATION THAT ENABLE COVALENT COUPLING OF AN HIV-1 ENV TRIMER TO THE SURFACE OF THE LNP. A NON-GMP PROCESS RUN OF DRUG PRODUCT SHALL BE PERF$253K
May 4, 2023Department of DefenseDEFENSE THREAT REDUCTION AGENCY541715ACCELERATED DEVELOPMENT OF A SARS-COV-2 VACCINE BASED ON THE LIVE VSVAG CHIMERIC VIRUS PLATFORM$3.2M
Feb 8, 2023Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID5417141800010I IAVI BASE AWARD $810,077 FY20 CELL LINE OPTIMIZATION AND PRE-MASTER BANK GENERATION FOR SB 301, A VACCINE FOR HEPATITIS B VIRUS (HBV) TOVM20V24VB 2 IID CAN 8470036$190K
Jan 10, 2023Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA541714THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN$30M
Dec 1, 2022Department of DefenseDEFENSE THREAT REDUCTION AGENCY541715ACCELERATED DEVELOPMENT OF A SARS-COV-2 VACCINE BASED ON THE LIVE VSVAG CHIMERIC VIRUS PLATFORM$1.1M
Sep 15, 2022Department of DefenseDEFENSE THREAT REDUCTION AGENCY541715ACCELERATED DEVELOPMENT OF A SARS-COV-2 VACCINE BASED ON THE LIVE VSVAG CHIMERIC VIRUS PLATFORM$5.3M
Sep 12, 2022Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA541714THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN$17M
Aug 30, 2022Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID541715PRECLINICAL AND TRANSLATIONAL VACCINE DEVELOPMENT FOR HIV AND OTHER CANDIDATE AGENTS$4.0M

Want to win work like International Aids Vaccine Initiative INC.?

Their contracts will eventually end — and when they do, the government has to award that work again. Mindy tells you up to a year early, so you can be ready to compete for it.